Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study

Background: Tumor mutational burden (TMB) is a potential biomarker to predict tumor response to immuno-oncology agents in patients with metastatic non-small cell lung cancer (NSCLC). Materials and Methods: A multi-site cohort study evaluated patients diagnosed with stage IV NSCLC between 2012 and 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Willis, Connor, Bauer, Hillevi, Au, Trang H., Menon, Jyothi, Unni, Sudhir, Tran, Dao, Rivers, Zachary, Akerley, Wallace, Schabath, Matthew B., Badin, Firas, Sekhon, Ashley, Patel, Malini, Xia, Bing, Gustafson, Beth, Villano, John L., Thomas, John-Michael, Lubinga, Solomon J., Cantrell, Michael A., Brixner, Diana, Stenehjem, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803368/
https://www.ncbi.nlm.nih.gov/pubmed/35111281
http://dx.doi.org/10.18632/oncotarget.28178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803368/
https://www.ncbi.nlm.nih.gov/pubmed/35111281
http://dx.doi.org/10.18632/oncotarget.28178

Ejemplares similares